Pulmonary hypertension in congenital diaphragmatic hernia

Hadi Mohseni-Bod1, Desmond Bohn

  • 1Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada.

Insights

Congenital diaphragmatic hernia (CDH) in newborns often causes pulmonary hypertension (PHTN), leading to heart and lung issues. Early intervention with PGE1 or iNO and supportive care improves outcomes for affected infants.

Area of Science:

  • Neonatal Medicine
  • Pediatric Cardiology
  • Pulmonology

Background:

  • Congenital diaphragmatic hernia (CDH) frequently presents with clinically significant pulmonary hypertension (PHTN) in neonates.
  • This PHTN can cause right-to-left shunting, hypoxemia, and acute right heart failure, even in infants without obvious ductal shunting.
  • Pulmonary vascular resistance and right ventricular pressures are often elevated in CDH, potentially persisting postnatally, with abnormal pulmonary vascular beds.

Purpose of the Study:

  • To review the pathophysiology and management of pulmonary hypertension in infants with congenital diaphragmatic hernia.
  • To highlight the impact of modern management strategies on mortality and morbidity.
  • To discuss therapeutic interventions and long-term follow-up for CDH patients.

Main Methods:

  • Review of clinical findings and diagnostic approaches for PHTN in CDH.
  • Discussion of established and emerging treatment modalities for PHTN in this population.
  • Emphasis on multidisciplinary care and long-term follow-up strategies.

Main Results:

  • "Gentle" ventilation, delayed surgery, and improved peri-operative care have significantly reduced mortality over the past two decades.
  • Prostaglandin E1 (PGE1) is recommended for hemodynamically significant PHTN with right ventricular dysfunction and restrictive patent ductus arteriosus (PDA).
  • Inhaled nitric oxide (iNO) may be beneficial, with response confirmation via echocardiography.

Conclusions:

  • Pulmonary hypertension is a critical issue in congenital diaphragmatic hernia requiring prompt recognition and management.
  • Pharmacological interventions like PGE1 and iNO play a role in managing PHTN, alongside optimized ventilation and surgical timing.
  • Long-term multidisciplinary follow-up is essential for managing chronic morbidities in survivors of CDH.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...